

## XANTHINE OXIDASE INHIBITORY EFFECTS OF *PISTACIA LENTISCUS* L. LEAVES EXTRACTS

RIHAB HADDI\*, ABDERRAZAK MAROUF\*\*

\*Laboratory of Plant Biochemistry and Natural Substances, Department of Biology, Faculty of Biology, University of Oran, Algeria,

\*\*Laboratory of Plant Biochemistry and Natural Substances, University Center of Naama, Algeria.

Email: rihabhaddi@yahoo.fr

Received: 08 Sep 2014 Revised and Accepted: 05 Oct 2014

### ABSTRACT

**Objective:** The aim of this study is to evaluate the inhibition of the xanthine oxydase (XO) by the crude extract of *Pistacia lentiscus* L. leaves and their subsequent fractions (chloroformic, ethyl acetate, butanolic and aqueous) in order to find a natural substitute which could have a superior effect of inhibiting XO activity and can be used as an alternative to allopurinol which is used in therapeutic and clinical management of gout.

**Methods:** The degree of XO inhibitory activity was determined by measuring the absorbance spectrophotometrically at 295 nm, which is associated with uric acid formation. The different extracts were subjected to chemical screening for preliminary identification of the secondary metabolites. Phenolic acids and flavonoids detected were quantitatively determined.

**Results:** The results have shown that the crude and ethyl acetate extracts were found to have XO inhibitory activity reaching more than 50 % at a concentration of 100 mg/mL (ethyl acetate fraction with 60.2 %, Necessary concentration to inhibit 50% of xanthine oxidase (IC<sub>50</sub>) = 2.50, the crude with 55.3 %, IC<sub>50</sub> = 2.57), for the butanolic fraction the inhibition reaches 17.5 %, the aqueous 15.4 % and chloroformic 4.5 %.

The comparison was also made with a positive control allopurinol at a concentration of 100µg/mL. The result shows a slight difference, allopurinol has exhibited the highest XO inhibitory activity (71.8 %).

The phytochemical tests show various fluorescence, the quantitative dosage of total phenolic compounds and flavonoids shows respectively a quantities of 246.7 mg gallic acid equivalent (GA) eq /g and 70.9 mg catechin equivalent (Cat) eq /g of lyophilized powder for the crude extract.

**Conclusion:** These results suggest that the crude and ethyl acetate extracts of *Pistacia lentiscus* leaves can be used as an alternative to allopurinol due to their high inhibition activity of XO.

**Keywords:** *Pistacia lentiscus* L, Xanthine oxydase inhibitor, TLC, Phenolic compounds, Flavonoids.

### INTRODUCTION

Xanthine Oxidase (EC 1.2.3.2.) is an enzyme responsible for catalyzing the oxidation of hypoxanthine to xanthine that subsequently generates uric acid [1]. XO is distributed most abundantly in the liver and intestine [2]. It acts at the end of a catabolic sequence of the purine nucleotide metabolism in humans and few other uricotelic species [3]. It generates superoxide radical (O<sub>2</sub><sup>-</sup>) during oxidation of substrates [2], subsequently plays an important role in various forms of inflammatory diseases [4], several types of tissue and vascular injuries [5], and chronic heart failure [6].

The overproduction and/or under excretion of the uric acid lead to the incidence of hyperuricemia such as gout and recurrent attacks of arthritis [7]. One of the therapeutic approaches to treat gout is the use of XO inhibitors [8, 3] that block the biosynthesis of uric acid from purine in the body [3] and it is believed that either by increasing the excretion of uric acid or reducing the uric acid production helps to reduce the risk of gout [9].

Allopurinol is one of the many known synthetic XO inhibitors that is widely used in the therapeutic and clinical management of gout [6]. Since, allopurinol generates superoxide [5], it gives inevitably rise to the severe adverse effects such as hepatitis [10], nephropathy, allergic reactions and 6-mercaptopurine toxicity, a fatal complication known as "allopurinol hypersensitivity syndrome" [11]. Therefore, there is an urgent need to search for new XO inhibitors.

The appropriate uses of botanical plants to treat various diseases are gaining new interest [3, 12-13]. The plants and their phytochemicals are worth to be explored as potential XO inhibitory as they are already used as food or food supplements for many years and found safe for human bodies [14]. Polyphenols [15], flavonoids [16, 17], coumarins [18], ellagic acid, valoneic acid dilactone (VAD) [3] have been reported to be potent plant-based XO inhibitors.

This research will contribute to value at best the potential health of the Algerian plants and in the treatment of the main degenerative pathologies which affect a big part of the population.

In this study we have select a plant from the Anacardiaceae family: *Pistacia lentiscus* L., our choice was based on the large therapeutic use of this plant by the algerian population.

*Pistacia lentiscus* L. is an evergreen shrub or tree of the Anacardiaceae family, is a dense bush with a strong characteristic aroma and green leaves, largely distributed in extreme ecosystems of Mediterranean basin [19]. *Pistacia lentiscus* L. has a long tradition in folk medicine dating from the times of the ancient Greeks [20]. It is used as an antibacterial [21] and antiulcer agent [22]. The aerial parts of this species have traditionally been used in mediterranean area as a popular cure for hypertension and possesses diuretic properties [23].

Flavonoid glycosides have been isolated from the arial parts of *Pistacia lentiscus* [24] and the polyphenolic composition of the leaves has also been reported [25, 26]. Presence of Triterpens [27], essentials oils [28, 29], saponins [27] and absence of alkaloids [30]. The leaves are used for the treatment of eczema, diarrhea and throat infections coughs, stomach aches, kidney stones and jaundice [22, 31, 32].

Therefore, this research aims to evaluate XO inhibitory activity from crude aqueous extracts of *Pistacia lentiscus* leaves and its subsequent fractions (chloroformic, ethyl acetate, butanolic and aqueous fractions) as to find a natural substitute of plant origin, which could have a superior effect of inhibiting XO activity and can be used as an alternative to allopurinol.

### MATERIALS AND METHODS

#### Chemicals and reagents

Zyloric® a drug containing allopurinol (100 mg, excipient: lactose) was used, xanthine and xanthine oxidase were purchased from

Sigma-Aldrich Chemicals, dimethylsulphoxide (DMSO), hydrochloric acid (HCl), sodium phosphate buffer (sodium dihydrogen phosphate ( $\text{NaH}_2\text{PO}_4$ , 2  $\text{H}_2\text{O}$ ) and disodium hydrogen phosphate ( $\text{Na}_2\text{HPO}_4$ , 12  $\text{H}_2\text{O}$ ) were purchased from Biochem Chemopharma. All organic solvents (analytical-reagent grade) and Thin Layer Chromatography (TLC) sheets (Silicagel 60 F<sub>254</sub>, 0.2 mm thickness) were purchased from Merck. Gallic acid, catechin, cinnamic acid, vanillic acid and ascorbic acid were obtained from Fluka Chemie.

### Plant material

Fully-expanded leaves were collected from adult plants of *Pistacia lentiscus* L. growing in Misserghin forest in north-west of Algeria at November 2007. The plant material was authenticated by Pr. Abderrazak MAROUF (University of Naama, Laboratory of Plant Biochemistry and Natural Substances).

### Preparation of plant extract

The leaves of *Pistacia lentiscus* were cut into small pieces and dried in hot air oven at 45 °C then grinded. The aqueous extract was prepared by refluxing (60 - 70 °C), 10 g of vegetal powder mixed with 100 mL of distilled water for 30 min. This operation was repeated thrice with fresh solvent each time, followed by filtration. Filtered extracts were collected and lyophilized to dryness.

### Fractionation

With the aim of separating the constituents of the aqueous extract, the lyophilized extract was partitioned by using three organic solvents of increasing polarities: chloroform ( $\text{CHCl}_3$ ), ethyl acetate (AcOEt) and *n*-butanol (*n*-BuOH) fig. 1.

The organics fractions were evaporated to dryness under vacuum (Büchi Rotavapor) and the aqueous fraction was lyophilized.

### Xanthine oxidase inhibitory activity assay

The inhibitory effect on XO was measured spectrophotometrically at 295 nm under aerobic condition, following the method reported by [3] and [9]. Allopurinol (100  $\mu\text{g}/\text{mL}$ ) was used as a positive control for the inhibition test.

The reaction mixture consisted of 300  $\mu\text{L}$  of 50 mM sodium phosphate buffer (pH 7.5), 100  $\mu\text{L}$  of sample solution at different concentrations (10, 25, 50, 75 and 100  $\text{mg}/\text{mL}$ ) dissolved in DMSO, 100  $\mu\text{L}$  of freshly prepared enzyme solution (0.2 units/mL of XO in phosphate buffer) and 100  $\mu\text{L}$  of distilled water.




Fig. 1: Liquid-liquid fractionation

The assay mixture was pre-incubated at 37 °C for 15 min. Then, 200  $\mu\text{L}$  of substrate solution (0.15 mM of xanthine) was added to the mixture which was incubated at 37 °C for 30 min. Next, the reaction was stopped with the addition of 200  $\mu\text{L}$  of 0.5 M HCl. The absorbance was measured using UV/VIS spectrophotometer (8500 P Double-Beam Spectrophotometer) against a blank prepared in the same way but the enzyme solution was replaced with the phosphate buffer. Another reaction mixture was prepared (control) having 100  $\mu\text{L}$  of DMSO instead of test sample in order to have maximum uric acid formation. The equation reported by [33] was used to evaluate the degree of XO inhibitory activity, in which  $\alpha$  is the activity of XO without test extract and  $\beta$  is the activity of XO with test extract.

$$\% \text{ XO inhibition} = (1 - \beta / \alpha) \times 100$$

XO inhibitory activity (%) is based on triplicate measurements and the results are expressed as means.

### Phytochemical screening

For each fraction of the plant, a phytochemical screening was performed for the presence of secondary metabolites by using TLC analyses. The development was performed on aluminum plates coated with silica gel 60 F<sub>254</sub>. The volume of each sample was 50  $\mu\text{L}$ , for the phenolic acids the volume used for each standard was 10  $\mu\text{L}$ . The chromatograms were analyzed under 254 and 365 nm UV light and then sprayed with specific reagents according to the class of compounds investigated. The solvent systems and the spray reagents are shown in table 1.

Table 1: Phytoconstituents, solvent systems and spray reagents [34]

Phytoconstituents	Solvent systems	Spray reagents
Flavonoids		Neu
Phenolic acids	Ethyl acetate: Formic acid: Acetic acid: water (100:11:11:26)	Folin-Ciocalteu
Terpenoids		Anisaldehyde
Sesquiterpene lactons		Zimmermann
Coumarins		KOH
Anthracenic derivatives		KOH
Alkaloids	Dichloromethan: Methanol: Amoniac hydroxide (95:5:0.5)	Dragendorff
Saponins	Chloroform: Methanol: Water (64:40: 8)	Komarowsky
Cardiotonic glycosides	Ethyl acetate: Methanol: Water (100: 13.5: 10)	Antimony chloride III (ASbCl <sub>3</sub> )
Free quinones	Ethyl acetate: Methanol: Water (100: 17: 13)	KOH
Lignans	Chloroform: Methanol: Water (70: 30: 4)	Vanilline H <sub>2</sub> SO <sub>4</sub>

### Determination of total phenolic compounds

The total phenolic compounds contents in the plant extracts were determined by colorimetric assay, using the Folin-Ciocalteu reagent [35] and gallic acid as a standard, aliquot of 100  $\mu\text{L}$  of the plant extracts in methanol was mixed thoroughly with 500  $\mu\text{L}$  of a 10 %

Folin-Ciocalteu reagent (in water). After 5 min of incubation in obscurity, 1.5 mL of a 2 % sodium bicarbonate ( $\text{NaCO}_3$ ) in water was added; the mixture was mixed and incubated for 1 h in obscurity. The absorbance was measured at 765 nm against blank prepared similarly, by replacing extract with methanol, using a spectrophotometer. The concentration of total phenolic compounds

was determined as mg of (GA) eq/g of lyophilized powder, using the equation obtained from the standard gallic acid curve.

**Determination of total flavonoids**

The total flavonoids content was determined using the method described by [36]. An aliquot of 500 µL of plant extracts in methanol was mixed with 1500 µL of distilled water followed by addition of 150 µL of a 5 % Sodium nitrate (NaNO<sub>2</sub>) in water and the mixture allowed to react for 5 min. Following this, 150 µL of a 10 % chloride of aluminium (AlCl<sub>3</sub>) in water was added and the mixture stood for further 6 min. Finally, the reaction mixture was treated with 500 µL of 1M sodium hydroxide (NaOH) in water and the absorbance at 510 nm was obtained against a blank prepared similarly, by replacing extract with methanol using a spectrophotometer. Total flavonoids content was calculated from a calibration curve using catechin as standard and expressed as mg of (Cat) eq/g of lyophilized plant extract. The experiment was done in triplicate.

**RESULTS**

**Xanthine oxidase inhibitory activity**

The evaluation of XO inhibitory activity of different extracts of *Pistacia lentiscus* (crude, chloroformic, ethyl acetate, butanolic and aqueous) were conducted at different concentrations. The results are shown in fig. 2.




Fig. 2: XO inhibitory activity (%) by crude extract and subsequent fractions of *Pistacia lentiscus*

The crude and ethyl acetate extracts were found to have XO inhibitory activity reaching more than 50 % at a concentration of 100 mg/mL. The highest XO inhibitors activity was the ethyl acetate fraction with 60.2 % (IC<sub>50</sub> = 2.50 mg/mL), the crude with 55.3 % (IC<sub>50</sub> = 2.57 mg/mL), butanolic 17.5 %, aqueous 15.4 % and chloroformic 4.5 %.

The comparison was also made between the different extracts of *Pistacia lentiscus* and the positive control allopurinol at a concentration of 100 µg/mL. The result shows a slight difference of the inhibition activity between the crude extract (55.3 %), ethyl acetate (62.3 %) and allopurinol which has exhibited the highest XO inhibitory activity (71.8 %). The results are shown in fig. 3.




Fig. 3: XO inhibitory activity (%) of the crude extract and subsequent fractions of *Pistacia lentiscus* at 100 mg/ml compared to allopurinol at 100 µg/ml

**Qualitative and quantitative analysis of the secondary metabolites**

The crude extract of *Pistacia lentiscus* leaves and its organic fractions were subjected to chemical screening for preliminary identification of the secondary metabolites that may be accounted for XO inhibitory activity employing previously described methodologies [34]. The results are recapitulated in table 2 and fig. 4.

Table 2: Phytochemical screening of *Pistacia lentiscus* extracts

Phytoconstituents	Crude extract	Chloroformic fraction	Ethyl acetate fraction	Butanolic fraction	Aqueous fraction
Phenolic acids	+++	-	+++	++	+
Flavonoids	+++	-	+++	++	+
Alkaloids	-	-	-	-	-
Saponins	+++	-	+++	++	++
Coumarins	++	-	++	+	-
Lignans	++	-	++	+	+
Free quinones	+++	-	+++	++	-
Sesquiterpene lactones	++	-	++	+	+
Triperpenes	++	-	++	+	+
Cardiotonic glycosides	+	-	+	+	-
Anthracenic derivatives	+	-	+	+	-

Strong presence: +++, moderate presence: ++, trace: +, negative result: -


The phytochemical tests carried out on the crude extract of *Pistacia lentiscus* and subsequent fractions (mainly in the ethyl acetate fraction) made it possible to highlight various fluorescences (yellow, yellow orange, yellow green, orange, blue green, blue, purple) which explain the presence of several classes of secondary metabolites: flavonols (yellow color), flavones (purple), anthocyanes (red color), phenolic acids as gallic acid and ascorbic acid, saponins, terpenoids, free quinones.

The secondary metabolites mainly phenolic acids and flavonoids detected in the crude extract of *Pistacia lentiscus* leaves were quantitatively determined according to the previously reported methodologies [35, 36].

The amount of total phenolics acids of the crude extract are obtained from a standard curve of gallic acid ( $y = 104.4x - 0.002$ ,  $R^2 = 0.996$ ). This extract contains 246.7 mg (GA) eq /g of lyophilized powder. Using the AlCl<sub>3</sub> reagent and catechin as standard ( $y = 0.0414x - 0.0026$ ,  $R^2 = 0.996$ ) the amount of total flavonoids is 70.9 mg (Cat) eq /g of lyophilized powder

**DISCUSSION**

The results obtained show the richness of the crude extract and ethyl acetate fraction of *Pistacia lentiscus* by diverse chemical structures of secondary metabolites (table 2, figure3). The leaves of *Pistacia lentiscus* contain mainly phenolic acids: vanillic acid, caffeic acid [37], gallic acid and derivatives, quinic acid and coumaric acid [38, 39].



**(a): Flavonoids, (b): Coumarins, (c): Terpenoids, (d): Alkaloids, (e): Phenolic acids, (f): Lignans,, (g): Saponins, (h): Sesquiterpens lactones**

**1: crude extract, 2: chloroformic fraction, 3: ethyl acetate fraction, 4: butanolic fraction, 5: aqueous fraction Samples of phenolic acids: GA: gallic acid, VA, vanilic acid, CA: cinnamic acid, AA: ascorbic acid**

**Fig. 4: Some of the secondary metabolites detected in the crude extract and subsequent fractions of *Pistacia lentiscus***

Several classes of flavonoids are also detected among flavones (luteolin, triclin and chrysoeriol), flavonols (myricetin, quercetin) and kaempferol [37, 39], anthocyanins (delphinidin 3-*O*-glucoside and cyanidin 3-*O*-glucoside) [38], triterpens [40] catechic and gallic tannins [30], heterosides (orientin, isoorientin, vitexin and rutin) [37] and saponins [40]. Concerning the detection of alkaloids, our results show the absence of these compounds which matches the study of Lamnaouer [30].

These compounds have a powerful antioxidant capacity, a capacity to decrease the peroxidation degree [41], as well as hepatoprotective, anti-inflammatory, and anticancer effects [37, 38, 39, 42].

Many studies estimated the inhibitive effect of various plants on the activity of XO [43,44,45], this inhibitive activity can be attributed to the presence of different bioactive compounds such as polyphenols [46], tannins [47] and flavonoids including myricetin, apigenin, quercetin and isovitexin [48,49], coumarins and kaempferol [15, 18, 50,51].

The results demonstrated a lower XO inhibitory activity in butanolic, aqueous and chloroformic fractions which is probably due to limited bioactive compounds presence depending on the solvent used for extraction.

The ethyl acetate solvent has shown better capacity to extract XO inhibitors, so better characteristic in obtaining high percentage of XO inhibitors activity [52].

Many studies showed that the flavonoids are natural inhibitors of XO and they act as competitive inhibitors by the existence of similarity between the cycle A of flavonoids and purinic noyau of hypoxanthine and xanthine [50,51]. These substances inhibit the XO by blocking the fixation of the substrate in active sites of enzyme [53].

Cos and collaborators [54] determined the relation between chemical structure of flavonoids and their inhibitive activity of XO. They showed the existence of double bounds between the carbons C2 and C3, and absence of hydroxyle groups in C3 increasing their inhibitive activity. They also showed that glycosyled flavonoids have lower activity than non glycosyled flavonoids, example the rutin is almost ten times less active than the quercetin.

Our result matches with the study of [55] which shows a XO inhibition of allopurinol starting from a concentration of 5 µg/mL. The highest percentage reaches a 93.69 % at a concentration of 100 µg/mL.

Based on these results, allopurinol remains the higher inhibitor used for the treatment of gout and other related-inflammatory diseases [6]. Due to the many side effects caused by allopurinol, it is better to utilize natural XO inhibitors instead of it. These results could be helpful in the use of *Pistacia lentiscus* leaves as an alternative to allopurinol.

## CONCLUSION

The aim of this research was to evaluate the inhibition of XO by different extracts of *Pistacia lentiscus* leaves in order to substitute a medicine (allopurinol) used in the treatment of gout.

The phytochemical screening of the crude extract and ethyl acetate fraction showed the presence of several classes of secondary metabolites mainly: phenolic acids and flavonoids which were quantified by spectrophotometer method. These two extracts presented the highest inhibitive activity of XO due to their abundance in bioactive compounds. These results suggest that the crude and ethyl acetate extracts of *Pistacia lentiscus* leaves can be used as an alternative to allopurinol.

## Corresponding author

Rihab HADDI, Laboratory of Plant Biochemistry and Natural Substances, Department of Biology, Faculty of Biology, University of Oran, Algeria.

## CONFLICT OF INTERESTS

Declared None

## REFERENCES

- Ramallo IA, Zacchino SA, Furlan RLE. A rapid TLC autographic method for the detection of xanthine oxidase inhibitors and superoxide scavengers. *Phytochem Anal* 2006;17(1):15-9.
- Battelli MG, Corte ED, Stirpe F. Xanthine oxidase type D (dehydrogenase) in the intestine and other organs of the rat. *Biochem J* 1972;126(3):747-9.
- Unno T, Sugimoto A, Kakuda T. Xanthine oxidase inhibitors from the leaves of *Lagerstroemia speciosa* (L.). *J Ethnopharmacol* 2004;93:391-5.
- Rohman A, Riyanto S, Yuniarti N, Saputra WR, Utami R, Mulatsih W. Antioxidant activity, total phenolic, and total flavonoid of extracts and fractions of red fruit (*Pandanus conoideus* Lam). *Int Res J* 2010;17:97106.
- Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: the molecular mechanisms and pathophysiological implications. *J Physiol* 2004;555(3):589-606.
- Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. *Pharmacol Rev* 2006;58(1):87-114.
- Virsaladze DK, Tetradze LO, Dzhavashvili LV, Esalia NG, Tananashvili DE. Levels of uric acid in serum in patients with metabolic syndrome. *Georgian Med News* 2007;146:35-7.
- Kong LD, Abliz Z, Zhou CX, Li LJ, Cheng CHK, Tan RX. Glycosides and xanthine oxidase inhibitors from *Conyza bonariensis*. *Phytochem* 2001;58(4):645-51.



9. Umamaheswari M, Asok Kumar K, Somasundaram A, Sivashanmugam T, Subhadradevi V, Ravi TK. Xanthine oxidase inhibitory activity of some Indian medicinal plants. *J Ethnopharmacol* 2007;109(3):547-51.
10. Fields M, Lewis CG, Lure MD. Allopurinol, an inhibitor of xanthine oxidase, reduces uric acid levels and modifies the signs associated with copper deficiency in rats fed fructose. *Free Radic Biol Med* 1996;20(4):595.
11. Kong LD, Zhang Y, Pan X, Tan RX, Cheng CHK. Inhibition of xanthine oxidase by liquiritigenin and isoliquiritigenin isolated from *Sinofranchetia chinensi*. *Cell Mol Life Sci* 2000;57:500-5.
12. Tapsell LC, Hemphill I, Cobiac L, Patch CS, Sullivan DR, Fenech M, et al. Health benefits of herbs and spices: the past, the present, the future. *Med J Aust* 2006;185(4):S4-S24.
13. Triggiani V, Resta F, Guastamacchia E, Sabba C, Licchelli B, Ghiyasaldin S, et al. Role of antioxidants, essential fatty acids, carnitine, vitamins, phytochemicals and trace elements in the treatment of diabetes mellitus and its chronic complications. *Endocrine, Metab Immune Disorders-Drug Targets* 2006;6(1):77-93.
14. Abd Aziz SM, Low CN, Chai LC, Abd Razak SSN, Selamat J, Son R, et al. Screening of selected Malaysian plants against several food borne pathogen bacteria. *Int Food Res J* 2011;18(3):1195-201.
15. Costantino L, Albasini A, Rastelli G, Benvenuti S. Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase. *Planta Med* 1992;58:342-4.
16. Chang WS, Lee YJ, Lu FJ, Chiang HC. Inhibitory effects of flavonoids on xanthine oxidase. *Anticancer Res* 1993;13:2165-70.
17. Selloum L, Reichl S, Muller M, Sebihi L, Arnhold J. Effects of flavonols on the generation of superoxide anion radicals by xanthine oxidase and stimulated neutrophils. *Arch Biochem Biophys* 2001;395(1):49-56.
18. Chang WS, Chiang HC. Structure-activity relationship of coumarins in xanthine oxidase inhibition. *Anticancer Res* 1995;15:1969-74.
19. Zrira S, Elamrani A, Benjlali B. Chemical composition of the essential oil of *Pistacia lentiscus* L. from Morocco-A seasonal variation. *Flavour Fragrance J* 2003;18:475-80.
20. Palevitch D, Yaniv Z. The effects of aqueous extracts prepared from the leaves of *Pistacia lentiscus* in experimental liver disease. *Medicinal plants of the holy land. modan publishing house, tel aviv, israel. in ljubuncic and al. J Ethnopharmacol* 2000;11:198-204.
21. Iauk L, Ragusa S, Rapisarda A, Franco S, Nicolosi VM. *In vitro* antimicrobial activity of *Pistacia lentiscus* L. extracts: preliminary report. *J Chemother* 1996;8:207-9.
22. Ali-Shtayeh MS, Yaghmour RMR, Faidi YR, Salem K, Al-Nuri MA. Antimicrobial activity of 20 plants used in folkloric medicine in the Palestinian area. *J Ethnopharmacol* 1998;60:265-71.
23. Sanz MJ, Milla'n MM. The dynamics of polluted air masses and ozone cycles in the western Mediterranean: relevance of forest ecosystems. *Chemosphere* 1998;36:1089-94.
24. Kawashty SA, Mosharrafa SAM, El-Gibali M, Saleh NAM. The flavonoids of four *Pistacia* species in Egypt. *Biochem Syst Ecol* 2000;28:915-7.
25. Romani A, Pinelli P, Galardi C, Mulinacci N, Tattini M. Identification and quantification of galloyl derivatives, flavonoid glycosides and anthocyanins in leaves of *Pistacia lentiscus* L. *Phytochem Anal* 2002;13:79-86.
26. Hamlat N, Hassani A, Ouafi S. Analyse des polyphénols extraits des feuilles du *Pistacia lentiscus*. Etude de l'activité antibactérienne. *Revue Des Régions Arides* 2008;21:306-16.
27. Villar A, Sanz MJ, Paya M. Hypotensive effect of *pistacia lentiscus* L. *Pharm Biol* 1987;25(1):1-3.
28. Dob T, Dahmane D, Chelghoum C. Chemical composition of the essential oils of *Pistacia lentiscus* L. from Algeria. *J Essent Oil Res* 2006;18:335-8.
29. Amhamdi H, Aouinti F, Wathelet JP, Elbachiri A. Chemical composition of the essential oil of *pistacia lentiscus* l. from eastern morocco. *Rec Nat Prod* 2009;3(2):90-5.
30. Lamnaouer D. Composition chimiques et activités biologiques de quelques plantes médicinales du PNT in Programme de l'UICN en Afrique du Nord: Phase III: Conduite d'essais d'extraction et d'analyse des huiles essentielles et des principes actifs des plantes médicinales et aromatiques. 2002.
31. Ali-Shtayeh MS, Yaniv Z, Mahajna J. Ethnobotanical survey in the Palestinian area: a classification of the healing potential of medicinal plants. *J Ethnopharmacol* 2000;73:221-32.
32. Chryssavgi G, Vassiliki P, Athanasios M, Kibouris Th, Michael K. Essential oil composition of *Pistacia lentiscus* L. and *Myrtus communis* L.: Evaluation of antioxidant capacity of methanolic extracts. *Food Chemistry* 2008;107:1120-30.
33. Naseem SA, Muhammad F, Muzammil HN, Kouser BM, Aurangzeb H. Activity of polyphenolic plant extracts as scavengers of free radicals and inhibitors of xanthine oxidase. *J Basic Appl Sci* 2006;2:1.
34. Wagner H, Blatt S. *Plant drug analysis: a thin layer chromatography atlas*. Second edition. Springer-Verlag, Berlin; 1996. p. 1-384.
35. Heilerova L, Buckova M, Tarapcik P, Silhar S, Labuda J. Comparison of antioxidative activity data for aqueous extracts of Lemon Blam (*Melissa officinalis* L.), Oregano (*Origanum vulgare* L.), Thyme (*Thymus vulgaris* L.) and Agrimony (*Agrimonia eupatoria* L.) obtained by conventional method and the DNA-based biosensor. *Czech J Food Sci* 2003;21:78-84.
36. Kim D, Jeong SW, Lee CY. Antioxidant capacity of phenolic phytochemicals from various cultivars of plums. *J Agric Food Chem* 2003;81:321-6.
37. Hamlat N, Hassani A, Ouafi S. Analyse des polyphénols extraits des feuilles du *Pistacia lentiscus*. Etude de l'activité antibactérienne. *Revue Des Régions Arides* 2008;21:306-16.
38. Romani A, Pinelli P, Galardi C, Mulinacci N, Tattini M. Identification and quantification of galloyl derivatives, flavonoid glycosides and anthocyanins in leaves of *Pistacia lentiscus* L. *Phytochem Anal* 2002;13:79-86.
39. Benhammou N, Atik Bekkara F, Kadifkova Panovska T. Antioxidant and antimicrobial activities of the *Pistacia lentiscus* and *Pistacia atlantica* extracts. *Afr J Pharm Pharmacol* 2008;2(2):22-8.
40. Villar A, Sanz MJ, Paya M. Hypotensive effect of *pistacia lentiscus* l. *Pharm Biol* 1987;25(1):1-3.
41. Ljubuncic P, Cogan U, Portnaya I, Azaizeh H, Said O, Bomzon A. Antioxidant activity and cytotoxicity of eight plants used in traditional Arab medicine in Israel. *J Ethnopharmacol* 2005;99:43-7.
42. Benhammou N, Atik Bekkara F, Kadifkova Panovska T. Antiradical capacity of the phenolic compounds of *Pistacia lentiscus* L and *pistacia atlantica* Desf. *Adv Food Sci* 2007;29(3):155-60.
43. Zhu JX, Wang Y, Kong LD, Yang C, Zhang X: Effects of *Biota orientalis* extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver. *J Ethnopharmacol* 2004;93:133-140.
44. Ferraz Filha ZS, Vitolo IF, Fietto LG, Lombardi JA, Saúde-Guimarães DA: Xanthine oxidase inhibitory activity of *Lychnophora* species from Brazil (Arnica). *J Ethnopharmacol* 2006;107:79-82.
45. Umamaheswari M, Asok-Kumar K, Somasundaram A, Sivashanmugam T, Subhadradevi V, Ravi TK: Xanthine oxidase inhibitory activity of some Indian medical plants. *J Ethnopharmacol* 2007;109:547-551.
46. Chiang HC, Lo YJ, Lu FJ: Xanthine oxidase inhibitions from leaves of *Alsophila spinulosa* (Hook) Tryon. *J Enzyme Inhib* 1994;8:61-71.
47. Schmeda-Hirschmann G, Zuniga J, Dutra-Behrens M, Habermehl G: Xanthine oxidase inhibitory activity of flavonoids and tannins from *Hexachlamys edulis* (Myrtaceae). *Phytotherapy Research* 1996;10:260-262.
48. Ponce AM, Blanco SE, Molina AS, Garcia-Domenech R, Galvez J: Study of the action of flavonoids on xanthine oxidase by molecular topology. *J Chem Inf Comput Sci* 2000;40:1039-45.
49. Lin CM, Chen CT, Chen YC. Liang and J-K: Molecular modeling of flavonoids that inhibits xanthine oxidase. *Biochem Biophys Res Commun* 2002;294:167-72.

50. Van Hoorn DEC, Nijveldt RJ, Van Leeuwen PAM, Hofman Z, M'Rabet L, De Bont DBA, *et al.* Accurate prediction of xanthine oxidase inhibition based on the structure of flavonoids. *Eur J Pharmacol* 2002;451:111-8.
51. Da Silva SL, Da Silva A, Honório KM, Marangoni S, Toyama MH, Da Silva ABF. The influence of electronic, steric and hydrophobic properties of flavonoid compounds in the inhibition of the xanthine oxidase. *J Mol Struct (Theochem)* 2004;684:1-7.
52. Ghosh A, Das BK, Roy A, Mandal B, Chandra G. Antibacterial activity of some medicinal plant extracts. *J Nat Med* 2007;62:259-62.
53. Sanders S, Eisenthal RS, Harrison R. NADH oxidase activity of human xanthine oxidoreductase- regeneration of superoxyde anion. *Eur J Biochem* 1997;245:541-8.
54. Cos P, Ying L, Calomme M, Hu JP, Cimanga K, Van-Poel B, *et al.* Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers. *J Nat Prod* 1998;61:71-6.
55. Azmi SMN, Jamal P, Amid A. Xanthine oxidase inhibitory activity from potential Malaysian medicinal plant as remedies for gout. *Int Food Res J* 2012;19(1):159-65.